Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.
1994; Rockefeller University Press; Volume: 179; Issue: 1 Linguagem: Inglês
10.1084/jem.179.1.341
ISSN1540-9538
AutoresQin L, Kenneth D. Chavin, Jianhua Lin, H Yagita, Jonathan S. Bromberg,
Tópico(s)T-cell and B-cell Immunology
ResumoIndefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.
Referência(s)